GILD Stock Analysis: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
$141.95
2.40 (1.72%)
ā²
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 10, 2026
9d
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called GILD this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
š HOLD: GILD is fairly valued with market pricing in 3.6% annual growth. Fine to hold or accumulate slowly on dips.
š HOLD: GILD is fairly valued with market pricing in 3.6% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$168.42
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$104.57
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GILD is currently trading at $141.95, which is considered extended relative to its 30-day fair value range of $120.13 to $134.17. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.9) compared to its historical average (14.3). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GILD is in a uptrend. The price is approaching resistance at $142.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GILD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GILD is in a uptrend. The price is approaching resistance at $142.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GILD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$120.13 -
$134.17
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
GILD is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.8% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($136.75)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$120.13 -
$134.17
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$122.10
Resistance Level
$142.20
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
15.89
Wall Street Target
$136.75
(-2.0%)
Revenue Growth (YoY)
3.0%
Earnings Growth (YoY)
143.0%
Profit Margin
27.9%
Valuation Premium vs History
+3.6% premium
PE vs Historical
15.9 vs 14.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$144.57
(+4%)
2-Year Target
$149.78
(+7%)
3-Year Target
$155.17
(+11%)
3-Yr Target (if PE normalizes)
(PE: 16ā14)
PE COMPRESSION
$139.67
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 8.1%)
$247.54
(+77%)
Base:
(SPY PE: 15.9, Growth: 8.1%)
$176.35
(+26%)
Bear:
(PE: 13.5, Growth: 8.1%)
$149.89
(+7%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 21.63 | Current EPS (TTM): $6.46
Bull Case
$208.99
(+47%)
Analyst growth 36.0%, PE expands to 23.8
Base Case
$189.99
(+34%)
Market implied 36.0%, PE stable at 21.6
Bear Case
$95.01
(-33%)
Severe decline -20.0%, PE contracts to 18.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 10:11 PM ET
Data refreshes hourly during market hours. Next update: 11:11 PM
Data refreshes hourly during market hours. Next update: 11:11 PM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GILD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Johanna Mercier
SELL
3000 shares
2025-10-15
Andrew D Dickinson
SELL
2500 shares
2025-10-15
Daniel Patrick O'day
SELL
10000 shares
2025-09-29
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$115 | 60 HOLD |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
